D
Daniel Dhumeaux
Researcher at French Institute of Health and Medical Research
Publications - 291
Citations - 23228
Daniel Dhumeaux is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Hepatitis C virus & Hepatitis C. The author has an hindex of 70, co-authored 291 publications receiving 22796 citations. Previous affiliations of Daniel Dhumeaux include University of Paris & Paul Sabatier University.
Papers
More filters
Journal ArticleDOI
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Michael W. Fried,Mitchell L. Shiffman,K. Rajender Reddy,C. Smith,George Marinos,Fernando L. Gonçales,Dieter Häussinger,Moisés Diago,Giampiero Carosi,Daniel Dhumeaux,Antonio Craxì,A. Lin,Joseph Hoffman,Jian Yu +13 more
TL;DR: In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferonAlfa- 2b plus Ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interfer on alfa -2b plus ribvirin or pegin terferonalfa-3a alone.
Journal ArticleDOI
Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C.
Marianne Ziol,Adriana Handra-Luca,Adrien Kettaneh,Christos Christidis,F. Mal,F. Kazemi,Victor de Ledinghen,Patrick Marcellin,Daniel Dhumeaux,Jean-Claude Trinchet,Michel Beaugrand +10 more
TL;DR: Noninvasive assessment of liver stiffness with transient elastography appears as a reliable tool to detect significant fibrosis or cirrhosis in patients with chronic hepatitis C.
Journal ArticleDOI
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.
Peter Ferenci,Michael W. Fried,Mitchell L. Shiffman,C. Smith,George Marinos,Fernando L. Gonçales,Dieter Häussinger,Moisés Diago,Giampero Carosi,Daniel Dhumeaux,Antonio Craxì,Monique Chaneac,K. Rajender Reddy +12 more
TL;DR: Early, sustained suppression of HCV replication portends an SVR, and cessation of treatment may be contemplated in patients without a > or = 2 log10 reduction in HCV RNA after 12 weeks.
Journal ArticleDOI
Immunological disorders in C virus chronic active hepatitis: A prospective case‐control study
Jean-Michel Pawlotsky,Mustapha Ben Yahia,Chantal Andre,Marie-Catherine Voisin,L Intrator,Françoise Roudot-Thoraval,Deforges L,Christophe Duvoux,Elie-Serge Zafrani,Jean Duval,Daniel Dhumeaux +10 more
TL;DR: The prevalences of cryoglobulinemia, rheumatoid factor and antitissue antibodies were significantly higher than those in the control group and patients with chronic hepatitis B, and can be classified into several categories.
Journal ArticleDOI
Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases.
Nathalie Ganne-Carrié,Marianne Ziol,Victor de Ledinghen,Catherine Douvin,Patrick Marcellin,Laurent Castera,Daniel Dhumeaux,Jean-Claude Trinchet,Michel Beaugrand +8 more
TL;DR: Fibroscan is a reliable method for the diagnosis of Cirrhosis in patients with chronic liver diseases, better at excluding than at predicting cirrhosis using a threshold of 14.6 kPa, and false‐negatives are mainly attributable to inactive or macronodular cirrhoses.